Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
REGULATORY
Japan OKs Omicron COVID-19 Vaccines from Pfizer, Moderna
The Japanese health ministry on September 12 approved two Omicron-adapted bivalent mRNA vaccines for COVID-19 developed respectively by Pfizer and Moderna, with an eye towards their rollout this month. The two vaccines - “Comirnaty RTU intramuscular injection (Bivalent: Original/Omicron BA.1)”…
To read the full story
Related Article
- Japan to Roll Out BA.4/5 Omicron Boosters on Oct. 13, Inoculations for 6 Months to 4 Years from Oct. 24
October 11, 2022
- MHLW Panel to Discuss Shortening of COVID Booster Interval
October 11, 2022
- Pfizer’s BA.4/5-Adapted Comirnaty Grabs Special Approval in Japan
October 6, 2022
- Pfizer Seeks Japan Nod for BA.4/5-Adapted COVID-19 Vaccine
September 13, 2022
- Pfizer/Moderna’s Omicron Vaccines on Japan Panel Agenda on Sept. 12
September 8, 2022
- Japan Govt to Start Omicron Vaccine Distribution from Week of Sept. 19
September 6, 2022
- Japan to Give Omicron Boosters to Elderly from Mid-September
September 5, 2022
- PM Kishida Vows Earlier Rollout of Omicron Boosters
September 1, 2022
- Japan Mulls Moving Up Omicron Boosters to September
August 31, 2022
- Moderna Files Omicron Bivalent Vaccine in Japan
August 10, 2022
- Japan to Begin BA.1-Based Omicron Booster Program as Early as October
August 9, 2022
- Pfizer Seeks Japan Nod for Omicron-Adapted Bivalent Jab
August 9, 2022
- MHLW Eyes Omicron-Specific Jabs for All Residents Given Primary Inoculations
July 26, 2022
- Omicron-Specific Boosters to Be Introduced This Fall or Later: Panel
July 25, 2022
REGULATORY
- Japan Approves Zepbound, Qalsody, and Lots More Drugs
December 27, 2024
- Quality Assurance and Lag/Loss Fight to Form Pillars of PMD Act Amendment
December 27, 2024
- LDP Members Urge Ministers to End “Mechanical” Off-Year Price Cuts
December 27, 2024
- Japan to Set Up Fund to Spur Generic Shakeup; CEA, Market Expansion Re-Pricing on Agenda
December 26, 2024
- Gist of FY2025 Drug Price Revision
December 26, 2024
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…